Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)
Sponsor: Sanofi Pasteur, a Sanofi Company
Terminated
Sponsor decision
Other terminated trials from Sanofi Pasteur, a Sanofi Company
Other RSV Immunisation trials with similar outcome
This PHASE3 trial investigates RSV Immunisation and is currently terminated or withdrawn. Sanofi Pasteur, a Sanofi Company leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Feb 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi Pasteur, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .